Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.

Eunice S Wang Aaron D GoldbergMartin TallmanRoland Bruno WalterChatchada KaranesKaramjeet SandhuCarlos Enrique Vigil Robert H CollinsVinay JainRichard M Stone

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

-mutant AML results in high rate of deep responses and long-term survival with acceptable toxicity. A randomized trial of crenolanib versus midostaurin plus chemotherapy in younger patients is ongoing.

Keyphrases

newly diagnosed
acute myeloid leukemia
end stage renal disease
ejection fraction
chronic kidney disease
locally advanced
allogeneic hematopoietic stem cell transplantation
prognostic factors
patient reported outcomes
patient reported